Pharma-Bio Serv, Inc (PBSV) Fair Value & Analysis
Healthcare · US · Market cap $13.1M
Fair value as of: Jun 25, 2026
Analysis
Pharma-Bio Serv, Inc (PBSV) currently trades at $0.5700, while our model-based Fair Value estimate is $0.1500 — implying the stock looks roughly 73.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support. It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Pharma-Bio Serv, Inc (PBSV) undervalued?
What is the fair value of PBSV?
What is the quality score of PBSV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.